Laurent Gouya

Laurent Gouya

Auto-generated profile, based on publicly available information

Laurent Gouya

INSERM U773, Centre de Recherche Biomédicale Bichat Beaujon CRB3, Université Paris 7 Denis Diderot, site Bichat, Paris, France

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in The Lancet
Verified
Journal Article
Closed access
HPHervé Puy
Hervé Puy
LGLaurent Gouya
Laurent Gouya
JDJean-Charles Deybach
Jean-Charles Deybach

8 July 2012 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CBCatherine Boileau
Catherine Boileau
DGDong-Chuan Guo
Dong-Chuan Guo
NHNadine Hanna
Nadine Hanna
EREllen S Regalado
Ellen S Regalado
DDDelphine Detaint
Delphine Detaint
DMDianna M. Milewicz
Dianna M. Milewicz
Dianna Milewicz and colleagues report the identification of loss-of-function mutations in TGFB2 in individuals with familial thoracic aortic aneurysm and acute aortic dissection associated with mild systemic features of the Marfan syndrome. A predisposition for thoracic aortic aneurysms leading to acute aortic dissections can be inherited in families in an autosomal dominant manner. Genome-wide linkage analysis of two large unrelated families with thoracic aortic disease followed by whole-exome sequencing of affected relatives identified causative mutations in TGFB2. These mutations—a frameshift mutation in exon 6 and a nonsense mutation in exon 4—segregated with disease with a combined logarithm of odds (LOD) score of 7.7. Sanger sequencing of 276 probands from families with inherited thoracic aortic disease identified 2 additional TGFB2 mutations. TGFB2 encodes transforming growth factor (TGF)-β2, and the mutations are predicted to cause haploinsufficiency for TGFB2; however, aortic tissue from cases paradoxically shows increased TGF-β2 expression and immunostaining. Thus, haploinsufficiency for TGFB2 predisposes to thoracic aortic disease, suggesting that the initial pathway driving disease is decreased cellular TGF-β2 levels leading to a secondary increase in TGF-β2 production in the diseased aorta.

1 September 2008 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
SWSharon D. Whatley
Sharon D. Whatley
SDSarah Ducamp
Sarah Ducamp
LGLaurent Gouya
Laurent Gouya
BGBernard Grandchamp
Bernard Grandchamp
CBCarole Beaumont
Carole Beaumont
HPHervé Puy
Hervé Puy

20 December 2001 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
LGLaurent Gouya
Laurent Gouya
HPHervé Puy
Hervé Puy
ARAnne-Marie Robreau
Anne-Marie Robreau
MBMonique Bourgeois
Monique Bourgeois
JLJerôme Lamoril
Jerôme Lamoril
JDJean-Charles Deybach
Jean-Charles Deybach

31 May 2013 in Haematologica
Verified
Journal Article
Closed access
LFLuigia De Falco
Luigia De Falco
MSMayka Sanchez
Mayka Sanchez
LSLaura Silvestri
Laura Silvestri
CKC. Kannengiesser
C. Kannengiesser
MMMartina Ulrike Muckenthaler
Martina Ulrike Muckenthaler
CBC. Beaumont
C. Beaumont
Iron refractory iron deficiency anemia is a hereditary recessive anemia due to a defect in the TMPRSS6 gene encoding Matriptase-2. This protein is a transmembrane serine protease that plays an essential role in down-regulating hepcidin, the key regulator of iron homeostasis. Hallmarks of this disease are microcytic hypochromic anemia, low transferrin saturation and normal/high serum hepcidin values. The anemia appears in the post-natal period, although in some cases it is only diagnosed in adulthood. The disease is refractory to oral iron treatment but shows a slow response to intravenous iron injections and partial correction of the anemia. To date, 40 different Matriptase-2 mutations have been reported, affecting all the functional domains of the large ectodomain of the protein. In vitro experiments on transfected cells suggest that Matriptase-2 cleaves Hemojuvelin, a major regulator of hepcidin expression and that this function is altered in this genetic form of anemia. In contrast to the low/undetectable hepcidin levels observed in acquired iron deficiency, in patients with Matriptase-2 deficiency, serum hepcidin is inappropriately high for the low iron status and accounts for the absent/delayed response to oral iron treatment. A challenge for the clinicians and pediatricians is the recognition of the disorder among iron deficiency and other microcytic anemias commonly found in pediatric patients. The current treatment of iron refractory iron deficiency anemia is based on parenteral iron administration; in the future, manipulation of the hepcidin pathway with the aim of suppressing it might become an alternative therapeutic approach.

1 January 2006 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
LGLaurent Gouya
Laurent Gouya
CSCaroline SCHMITT
Caroline SCHMITT
ARAnne-Marie Robreau
Anne-Marie Robreau
FAFrédéric Austerlitz
Frédéric Austerlitz
VSVasco Da Silva
Vasco Da Silva
JDJean-Charles Deybach
Jean-Charles Deybach